Continous Rituximab treatment for recurrent diffuse alveolar hemorrhage in a patient with systemic lupus erythematosus and antiphosholipid syndrome

@inproceedings{Aakjr2017ContinousRT,
  title={Continous Rituximab treatment for recurrent diffuse alveolar hemorrhage in a patient with systemic lupus erythematosus and antiphosholipid syndrome},
  author={Signe Aakj{\ae}r and Elisabeth Bendstrup and Per Raml\ov Ivarsen and Line Madsen},
  booktitle={Respiratory medicine case reports},
  year={2017}
}
Diffuse alveolar hemorrhage (DAH) is a rare but potentially fatal complication in systemic lupus erythematosus (SLE). DAH is typically characterized by hemoptysis, dyspnea, new infiltrates on chest x-rays or CT-scans and a drop in hemoglobin. DAH is seen in less than 2% of patients with SLE and carries a high acute mortality risk of up to 70-90%. The current treatment of DAH is high-dose intravenous corticosteroids, cyclophosphamide and extensive supportive care. Plasmapheresis is also often… CONTINUE READING
1 Citations
20 References
Similar Papers

Citations

Publications citing this paper.

References

Publications referenced by this paper.
Showing 1-10 of 20 references

L

  • M. L. Rangel, I. Alghamdi, G. Contreras, T. Harrington, D. B. Thomas
  • Barisoni, et al., Catastrophic antiphospholipid…
  • 2017
1 Excerpt

M

  • T. Isshiki, K. Sugino, K. Gocho, K. Furuya, H. Shimizu
  • Sekiya, et al., Primary antiphospholipid syndrome…
  • 2015
1 Excerpt

Recurrent di ff use alveolar haemorrhage in a patient with systemic lupus erythematosus : long - term bene fi t of ritux

  • C. Abud-Mendoza M. U. Martínez-Martínez
  • 2012

Similar Papers

Loading similar papers…